I migliori medici di Terapia con Lutetio-177 a Tel Aviv - TOP-4 medici

Il Prof. Merimsky dirige l'Unità di Oncologia Ortopedica presso il Centro Medico Sourasky, specializzandosi in terapie avanzate come il Lutetio-177.

• Oltre 25 anni di esperienza in oncologia e trattamento dei sarcomi
• Membro della facoltà ESMO per sarcomi dei tessuti molli e delle ossa
• Formazione specialistica presso l'Istituto Gustave Roussy di Parigi
• Pubblicazioni estese su malignità ossee e dei tessuti molli

Esperto leader nella terapia con Lutetium-177 – Il Dr. Raphael integra il profilo genomico all'avanguardia con trattamenti mirati con radionuclidi presso il Sourasky Medical Center.

• Docente senior e PI per numerosi studi clinici in oncologia
• Specializzato in neoplasie toraciche e studi clinici di fase avanzata
• Membro di ESMO e IASLC, si concentra su trattamenti innovativi
• Leader dell'Iniziativa Nazionale Israeliana di Medicina Genomica in oncologia
• Insegnante eccezionale presso la Facoltà di Medicina dell'Università di Tel-Aviv

Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.

Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.

Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.

This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.

Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.

In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!

All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.

Education

2000-1994 Faculty of Medicine in Vitebsk, Belarus.

Specialization

2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.

Recognized experience

Oncology and radiation therapy

Additional education

2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors

Attending conferences

About 10 presentations at medical conferences

Trade union membership

• Israel Society of Clinical Oncology and Radiotherapy ISCORT
• American Association of Radiation Therapy ASTRO
• Israel Head and Neck Oncology Association
• Areas of special interest and activities
• Radiation therapy in children
• Radiobiological treatment PRBT
• Radiation therapy for gastrointestinal tumors
• Treatment of head and neck tumors and skin tumors